CTOs on the Move

Ovid Therapeutics

www.ovidrx.com

 
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovidrx.com
  • 1460 Broadway
    New York, NY USA 10036
  • Phone: 646.661.7661

Executives

Name Title Contact Details
Stephanie Licata
 VP, Program Leadership & Portfolio Management Profile

Funding

Ovid Therapeutics raised $75M on 08/11/2015
Ovid Therapeutics raised $25.86M on 01/23/2017
Ovid Therapeutics raised $25M on 02/26/2019
Ovid Therapeutics raised $20M on 02/26/2019

Similar Companies

Business Health Services

Business Health Services is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atrion Corporation

Scherago International

Scherago International is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

.decimal

.decimal is a Sanford, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MaxIT Vitalize an SAIC company

MaxIT Vitalize an SAIC company is a Westfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.